This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026.
To view the full press release, visit https://ibn.fm/4IZ0y
In brief
Quantum BioPharma Ltd. says enrollment has reached the halfway point in its multiple sclerosis imaging study conducted with Massachusetts General Hospital. The study uses the [¹⁸F]3F4AP PET tracer to assess demyelination. The company reports that preliminary imaging has shown a signal in acute MS lesions and may be sensitive to gray matter lesions. Quantum says the technique could support development of MS treatments, including its investigational candidate Lucid-MS. The release also notes that an investigational new drug submission for a Phase 2 Lucid-MS trial was submitted to the FDA in March 2026. The company describes Lucid-MS as a patented compound studied in preclinical models.
Key takeaways
- Enrollment in the collaborative MS imaging study has reached the halfway mark, Quantum BioPharma says.
- The study uses the [¹⁸F]3F4AP PET tracer to assess demyelination.
- Preliminary imaging showed a signal in acute MS lesions and possible sensitivity to gray matter lesions, according to the company.
- Quantum says the imaging approach could support development of MS therapies, including Lucid-MS.
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What is the study evaluating?
The study is evaluating a PET imaging technique using the [¹⁸F]3F4AP tracer to assess demyelination directly. The company said the technique could help support development of multiple sclerosis therapies, including its investigational candidate Lucid-MS.
What is the status of Lucid-MS’s Phase 2 trial?
The release says an Investigational New Drug (IND) submission for a Phase 2 trial of Lucid-MS was submitted to the U.S. Food and Drug Administration in March 2026. It does not report that the trial has begun or that the FDA has cleared the submission.
What is demyelination?
Demyelination is damage to or loss of myelin, the protective insulating material around nerve fibers. When myelin is damaged, signals traveling along nerves may be disrupted. It can occur in multiple sclerosis, although the causes and effects can vary among conditions and individuals.
